MedPath

ABX advanced biochemical compounds GmbH

ABX advanced biochemical compounds GmbH logo
🇩🇪Germany
Ownership
Subsidiary
Established
1997-01-01
Employees
251
Market Cap
-
Website
http://www.abx.de

Clinical Trials

4

Active:1
Completed:1

Trial Phases

1 Phases

Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 3
3 (100.0%)

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Phase 3
Recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2023-11-08
Last Posted Date
2024-07-30
Lead Sponsor
ABX advanced biochemical compounds GmbH
Target Recruit Count
380
Registration Number
NCT06122584
Locations
🇫🇷

CHRU de Nancy, Nancy, France

🇪🇸

Hospital Del Mar, Barcelona, Spain

🇪🇸

Hospital Vithas Valencia 9 de Octubre, Valencia, Spain

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Phase 3
Active, not recruiting
Conditions
Prostate Cancer
Prostate Cancer Recurrent
Interventions
First Posted Date
2021-02-08
Last Posted Date
2024-07-30
Lead Sponsor
ABX advanced biochemical compounds GmbH
Target Recruit Count
136
Registration Number
NCT04742361
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States

and more 3 locations

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

Phase 3
Completed
Conditions
Prostate Cancer Recurrent
Prostate Cancer
Interventions
Drug: F-18-PSMA-1007
Drug: F-18-Fluorocholine
First Posted Date
2019-09-25
Last Posted Date
2021-06-29
Lead Sponsor
ABX advanced biochemical compounds GmbH
Target Recruit Count
200
Registration Number
NCT04102553
Locations
🇫🇷

Centre Jean Perrin Clermont-Ferrand, Clermont-Ferrand, France

🇫🇷

Centre Léon Bérard LUMEN, Lyon, France

🇫🇷

Hôpitaux de Brabois (Vandoeuvre-les-Nancy), Nancy, France

and more 3 locations

News

Primo Biotechnology Raises NT$220M Series A to Advance Radioligand Theranostics Platform

Primo Biotechnology completed a NT$220 million Series A funding round, bringing total capital raised to over NT$500 million to accelerate radioligand theranostics development.

Primo and ABX Partner to Introduce Advanced PSMA-Targeting Radiotracer for Prostate Cancer Diagnosis in Taiwan

Primo Biotechnology has formed a strategic partnership with Germany's ABX to introduce PB01, an advanced diagnostic radiotracer for prostate cancer, to the Taiwanese market amid rising disease incidence and mortality rates.

© Copyright 2025. All Rights Reserved by MedPath